Sort
1,049,261 grants matching “t cell”
Resource for Integrated Glycotechnology
$1,975,106James H Prestegard · University Of Georgia · P41 · FY2012 · GM
IDENTIFYING GENES IN ABNORMAL BLOOD PRESSURE
$1,975,093Boston University Medical Campus · P50 · FY2004 · HL
BACE1 as a Therapeutic Target for Alzheimer's Disease
$1,975,000Robert J Vassar · Northwestern University At Chicago · RF1 · FY2019 · AG
Understanding and Targeting Wild-Type SS18 Function and Stability in Synovial Sarcoma
$1,975,000Ali Shilatifard · Dana-Farber Cancer Inst · U54 · FY2018 · CA
DIOXIN TOXIC EQUIVALENCY FACTORS--BATTELLE MEMORIAL INST
$1,975,000Battelle Memorial Institute · N01 · FY2000 · ES
T LYMPHOCYTES AND CYTOKINES IN ASTHMA
$1,974,955Yale University · P50 · FY2000 · HL
Regulation Of Epidermal Differentiation
$1,974,901Maria Morasso · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2021 · AR
Melanoma and Skin Cancer Program SPORE
$1,974,834Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2023 · CA
Gene regulatory elements, networks, and mechanisms
$1,974,775Raja Jothi · National Institute Of Environmental Health Sciences · ZIA · FY2025 · ES
Shaping Antiviral Immunity by the Inflammatory, Regulatory and Tissue Environment
$1,974,689E. John Wherry · University Of Pennsylvania · U19 · FY2010 · AI
NANOSCALE SCREENS OF CHEMICAL LIBRARIES FOR CANCER DRUGS
$1,974,664Harvard University (Medical School) · P01 · FY2000 · CA
Molecular Pathways to Thymic Lymphoma and Leukemia
$1,974,630A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2008 · CA
Host-Tumor Cell Interactions in Myeloma:
$1,974,474Dana-Farber Cancer Institute · P01 · FY2004 · CA
Host-tumor cell interaction in myeloma: therapeutic applications
$1,974,463Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2012 · CA
Molecular Mechanisms of Blood Cell Transfusion
$1,974,406Leslie Eric Silberstein · Boston Children'S Hospital · P01 · FY2014 · HL
Translational Research in Breast Cancer
$1,974,356Xiang Zhang · Baylor College Of Medicine · P50 · FY2023 · CA
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
$1,974,282Anthony Andrew Oliva · Longeveron, Llc · R44 · FY2020 · AG
Vaccination against mucosal HIV clade C transmission
$1,974,218Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · P01 · FY2009 · AI
TOLERANCE--AN APPROACH TO CARDIAC ALLO &XENOTRANSPLANTS
$1,974,144Massachusetts General Hospital · P01 · FY2000 · HL
DEVELOPMENTAL BIOLOGY OF HUMAN ERYTHROPOIESIS
$1,974,140Stuart H Orkin · Boston Children'S Hospital · P01 · FY2015 · HL
Engineered Cardiac Morphogenesis-Stem Cells and Scaffolds
$1,974,136Buddy D Ratner · University Of Washington · R01 · FY2008 · HL
Data Coordinating Center for the Type 1 Diabetes in Acute Pancreatitis Consortium
$1,974,110Vernon M. Chinchilli · Pennsylvania State Univ Hershey Med Ctr · U01 · FY2025 · DK
Preserving Renal Function & Protective Immunity Via Anti-LFA1-Based CNI Avoidance
$1,974,106Kenneth A Newell · Emory University · U01 · FY2012 · AI
Sirtuins and nuclear receptors in aging and age-associated diseases
$1,974,079Xiaoling Li · National Institute Of Environmental Health Sciences · ZIA · FY2014 · ES
Chicago Tri-Institutional Center for Chemical Methods and Library Development
$1,974,060Sergey A Kozmin · University Of Chicago · P50 · FY2010 · GM